{"id":254894,"date":"2026-01-24T06:43:06","date_gmt":"2026-01-24T06:43:06","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/254894\/"},"modified":"2026-01-24T06:43:06","modified_gmt":"2026-01-24T06:43:06","slug":"rheumatoid-arthritis-has-no-cure-but-researchers-are-homing-in-on-preventing-it-2","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/254894\/","title":{"rendered":"Rheumatoid arthritis has no cure \u2013 but researchers are homing in on preventing it"},"content":{"rendered":"<p>But multiple studies have\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1136\/ard-2023-224211\" rel=\"nofollow noopener\">now confirmed that rheumatoid arthritis<\/a>\u00a0has a\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1136\/annrheumdis-2021-220884\" rel=\"nofollow noopener\">preclinical stage of development<\/a>. This is a time about three to five years or longer, prior to the onset of swollen joints when markers like rheumatoid factor and anti-cyclic citrullinated peptide are detectable in the blood. The presence of these markers indicates that autoimmunity is occurring, yet the body and organs are still functioning well, and a person who is at risk of getting rheumatoid arthritis may not feel sick yet.<\/p>\n<p>Now that researchers have identified this preclinical stage, health care providers can use markers such as autoantibodies and symptoms like prolonged early morning joint stiffness to identify people who are at risk for rheumatoid arthritis but do not yet have joint inflammation.<\/p>\n<p>At this point, predicting future rheumatoid arthritis is\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.7326\/M23-0272\" rel=\"nofollow noopener\">still in the research stage<\/a>, although the field is working toward established ways to\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1016\/j.ard.2025.01.021\" rel=\"nofollow noopener\">test for risk for rheumatoid arthritis<\/a>\u00a0as a routine part of health care. This is akin to how cardiovascular disease risk is assessed through measuring cholesterol levels.<\/p>\n<p>Ongoing research<\/p>\n<p>Because of advances in the ability to predict who may get rheumatoid arthritis in the future, researchers are now working on identifying treatments that can delay or prevent the full-blown condition from developing.<\/p>\n<p>In particular,\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1002\/art.43366\" rel=\"nofollow noopener\">trials have been performed<\/a>\u00a0in people who\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1136\/annrheumdis-2017-212763\" rel=\"nofollow noopener\">tested positive for anti-cyclic citrullinated peptide<\/a>, or who have\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1016\/s0140-6736(22)01193-x\" rel=\"nofollow noopener\">other risk factors<\/a>\u00a0for rheumatoid arthritis. These risk factors include joint pain and subclinical joint inflammation, which is when an imaging study, like magnetic resonance imaging, sees joint inflammation that can\u2019t be seen by a clinician examining the joints.<\/p>\n<p>To date, almost all of these trials have used immune drugs that are commonly used to treat full-blown rheumatoid arthritis, such as\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/my.clevelandclinic.org\/health\/drugs\/20143-methotrexate\" rel=\"nofollow noopener\">methotrexate<\/a>,\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/www.mayoclinic.org\/drugs-supplements\/hydroxychloroquine-oral-route\/description\/drg-20064216\" rel=\"nofollow noopener\">hydroxychloroquine<\/a>\u00a0and\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/my.clevelandclinic.org\/health\/drugs\/19712-rituximab-injection\" rel=\"nofollow noopener\">rituximab<\/a>. Researchers have been testing whether a short course of any of these drugs could lead to a lasting reset of the immune system and prevent rheumatoid arthritis from developing.<\/p>\n<p>While there is not yet an approved drug for rheumatoid arthritis prevention, these studies offer hope that researchers are on track to find the right drug \u2013 as well as the right dosage and duration of that drug.<\/p>\n<p>Researching the preclinical stage of rheumatoid arthritis<\/p>\n<p>Some challenges remain to be addressed before preventive treatments become the norm in clinical care.<\/p>\n<p>First, researchers need to better understand the biology of the preclinical stage of disease. Until recently, most studies have focused on patients with full-blown arthritis and generally ignored people at risk for developing the disease.<\/p>\n<p>But now, researchers can use blood markers like anti-cyclic citrullinated peptide antibodies to identify those who are at risk much more easily. And\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1038\/s41584-024-01154-0\" rel=\"nofollow noopener\">a growing number of studies<\/a>\u00a0of people with this marker\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.3389\/fimmu.2022.899372\" rel=\"nofollow noopener\">are informing<\/a>\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1002\/art.38273\" rel=\"nofollow noopener\">how scientists understand<\/a>\u00a0the biology of\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1172\/JCI185217\" rel=\"nofollow noopener\">rheumatoid arthritis development<\/a>.<\/p>\n<p>In particular, it is now apparent that the preclinical stage is marked by multiple circulating\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1126\/scitranslmed.adt7214\" rel=\"nofollow noopener\">immune system abnormalities in cells<\/a>, autoantibodies and inflammation. The hope is that researchers will find interventions that effectively target the immune system abnormalities driving the development of rheumatoid arthritis before the patient\u2019s joints begin to swell.<\/p>\n<p>Researchers are also finding that the abnormalities in the immune system during the preclinical stage may be coming from sites in the body other than the joints. An emerging idea called the\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1038\/s41584-024-01154-0\" rel=\"nofollow noopener\">mucosal origins hypothesis<\/a>\u00a0posits that the early autoimmunity of rheumatoid arthritis is caused by inflammation at mucosal surfaces of the body, such as the gums, the lungs and the gut. According to this theory, the joints are involved only later as the disease progresses.<\/p>\n<p>More research is needed, but the mucosal origins hypothesis may help explain why\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.3390\/ijms20184541\" rel=\"nofollow noopener\">periodontal disease<\/a>,\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1016\/j.amjmed.2005.09.053\" rel=\"nofollow noopener\">emphysema or other forms of lung disease<\/a>\u00a0and\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1002\/art.43113\" rel=\"nofollow noopener\">exposure to tobacco or forest fire smoke<\/a>\u00a0are risk factors for rheumatoid arthritis. It would also explain why\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.1126\/scitranslmed.abn5166\" rel=\"nofollow noopener\">certain bacteria<\/a>\u00a0have been\u00a0<a aria-label=\"content\" target=\"_blank\" href=\"https:\/\/doi.org\/10.3390\/jcm8111837\" rel=\"nofollow noopener\">associated with the disease<\/a>. Future trials targeting interventions to a mucosal process could help researchers better understand the nature of this disease.<\/p>\n","protected":false},"excerpt":{"rendered":"But multiple studies have\u00a0now confirmed that rheumatoid arthritis\u00a0has a\u00a0preclinical stage of development. This is a time about three&hellip;\n","protected":false},"author":2,"featured_media":254895,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[20683,3174,4399,66917,163,85,46,13961,83276,43,23974,7307],"class_list":{"0":"post-254894","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-arthritis","9":"tag-autoimmune-diseases","10":"tag-clinical-trials","11":"tag-disease-prevention","12":"tag-health","13":"tag-il","14":"tag-israel","15":"tag-joint-pain","16":"tag-joints","17":"tag-news","18":"tag-rheumatoid-arthritis","19":"tag-rheumatology"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/254894","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=254894"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/254894\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/254895"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=254894"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=254894"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=254894"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}